ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 224,81
-0,81%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Cara Therapeutics Inc (CARA)

  7. Cara Therapeutics Inc (CARA) Actualités

CARA Cara Therapeutics Inc

0,6843
-0,0157 (-2,24%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Cara Therapeutics Inc CARA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0157 -2,24% 0,6843 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,69 0,68 0,7264 0,6843 0,70
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/4/202413:00GLOBECara Therapeutics to Present at the 23rd Annual Needham..
07/3/202413:00GLOBECara Therapeutics to Host Notalgia Paresthetica (NP) Virtual..
06/3/202422:45EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/3/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:10EDGAR2Form 8-K - Current report
04/3/202422:01GLOBECara Therapeutics Announces Fourth Quarter and Full Year..
14/2/202400:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:01GLOBECara Therapeutics to Announce Fourth Quarter and Full Year..
05/2/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:59EDGAR2Form 8-K - Current report
29/1/202421:26EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202422:19EDGAR2Form 8-K - Current report
22/1/202413:00GLOBECara Therapeutics Prioritizes Late-Stage Notalgia..
18/12/202313:10EDGAR2Form 8-K - Current report
18/12/202313:00GLOBECara Therapeutics Announces Outcome from Dose-Finding Part A..
13/11/202322:28EDGAR2Form 8-K - Current report
13/11/202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:11EDGAR2Form 8-K - Current report
13/11/202322:01GLOBECara Therapeutics Reports Third Quarter 2023 Financial..
03/11/202321:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202312:10EDGAR2Form 8-K - Current report
02/11/202312:00GLOBECara Therapeutics Announces up to $40.0 Million Non-Dilutive..
23/10/202313:00GLOBECara Therapeutics to Announce Third Quarter 2023 Financial..
25/9/202313:00GLOBECara Therapeutics Announces Approval of KORSUVA® IV..
05/9/202313:00GLOBECara Therapeutics to Present at the H.C. Wainwright 25th..
07/8/202322:24EDGAR2Form 8-K - Current report
07/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:10EDGAR2Form 8-K - Current report
07/8/202322:01GLOBECara Therapeutics Reports Second Quarter 2023 Financial..
04/8/202323:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202323:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202313:06EDGAR2Form 8-K - Current report
03/8/202313:00GLOBECara Therapeutics Appoints Helen M. Boudreau to Board of..
02/8/202313:00GLOBECara Therapeutics to Present at the Canaccord Genuity 43rd..
25/7/202322:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/7/202313:00GLOBECara Therapeutics to Announce Second Quarter 2023 Financial..
03/6/202300:46PRNUSPalo Alto Networks Set to S&P 500; Others to Join S&P MidCap..
01/6/202313:00GLOBECara Therapeutics to Present at the Jefferies Healthcare..
18/5/202308:00GLOBEKapruvia® (difelikefalin) recommended by England’s NICE for..
15/5/202322:01GLOBECara Therapeutics Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
CARA
Cara Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés